Terms: = Prostate cancer AND LCK, YT16, 3932, P06239, ENSG00000182866, p56lck, pp58lck
12 results:
1. Discovery of a novel long noncoding RNA overlapping the lck gene that regulates prostate cancer cell growth.
Ta HQ; Whitworth H; Yin Y; Conaway M; Frierson HF; Campbell MJ; Raj GV; Gioeli D
Mol Cancer; 2019 Jun; 18(1):113. PubMed ID: 31253147
[TBL] [Abstract] [Full Text] [Related]
2. Myeloid-derived suppressor cells inhibit T cell activation through nitrating lck in mouse cancers.
Feng S; Cheng X; Zhang L; Lu X; Chaudhary S; Teng R; Frederickson C; Champion MM; Zhao R; Cheng L; Gong Y; Deng H; Lu X
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):10094-10099. PubMed ID: 30232256
[TBL] [Abstract] [Full Text] [Related]
3. Association between pathologic factors and ERG expression in prostate cancer: finding pivotal networking.
Lee SR; Choi YD; Cho NH
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1665-1683. PubMed ID: 29948147
[TBL] [Abstract] [Full Text] [Related]
4. Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
Noguchi M; Koga N; Moriya F; Suekane S; Yutani S; Yamada A; Shichijo S; Kakuma T; Itoh K
Cancer Sci; 2018 Sep; 109(9):2660-2669. PubMed ID: 29938870
[TBL] [Abstract] [Full Text] [Related]
5. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract] [Full Text] [Related]
6. Tebrophen--an old polyphenol drug with anticancer potential.
Rubelj I; Stepanić V; Jelić D; Vidaček NŠ; Kalajžić AĆ; Ivanković M; Nujić K; Matijašić M; Verbanac D
Molecules; 2012 Jun; 17(7):7864-86. PubMed ID: 22743590
[TBL] [Abstract] [Full Text] [Related]
7. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract] [Full Text] [Related]
8. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
Pacey S; Wilson RH; Walton M; Eatock MM; Hardcastle A; Zetterlund A; Arkenau HT; Moreno-Farre J; Banerji U; Roels B; Peachey H; Aherne W; de Bono JS; Raynaud F; Workman P; Judson I
Clin Cancer Res; 2011 Mar; 17(6):1561-70. PubMed ID: 21278242
[TBL] [Abstract] [Full Text] [Related]
9. Identification of lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles.
Naito M; Komohara Y; Ishihara Y; Noguchi M; Yamashita Y; Shirakusa T; Yamada A; Itoh K; Harada M
Br J Cancer; 2007 Dec; 97(12):1648-54. PubMed ID: 18043580
[TBL] [Abstract] [Full Text] [Related]
10. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.
Pantuck AJ; van Ophoven A; Gitlitz BJ; Tso CL; Acres B; Squiban P; Ross ME; Belldegrun AS; Figlin RA
J Immunother; 2004; 27(3):240-53. PubMed ID: 15076142
[TBL] [Abstract] [Full Text] [Related]
11. [Gene expression profiles of protein kinases and phosphatases obtained by hybridization with cDNA arrays: molecular portrait of human prostate carcinoma].
Kniazev IuP; Cheburkin IuV; Spikermann K; Peter S; Jenster G; Bangma KH; Karelin MI; Shkol'nik MI; Urbanskiĭ AI; Evtushenko VI; Ullrich A; Kniazev PG
Mol Biol (Mosk); 2003; 37(1):97-111. PubMed ID: 12624952
[TBL] [Abstract] [Full Text] [Related]
12. A tyrosine kinase profile of prostate carcinoma.
Robinson D; He F; Pretlow T; Kung HJ
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5958-62. PubMed ID: 8650201
[TBL] [Abstract] [Full Text] [Related]
